The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Disability as an outcome in MS clinical trials
Abstract
BACKGROUND: Inferences about long-term effects of therapies in multiple sclerosis (MS) have been based on surrogate markers studied in short-term trials. Preventing progressive disability is the key therapeutic goal but there remains no validated definition for its measurement in a trial context. Meanwhile, MS trials continue to shorten and to depend on unvalidated surrogates. Since there have been no treatment claims for improving unremitting disability, worsening of disability in the placebo/control arm must occur for effectiveness on this outcome to be shown. METHODS: We examined widely-used clinical surrogates of long-term disability progression in individual patients with MS within a unique database from the placebo arms of 31 randomized clinical trials. RESULTS: Detection of treatment effects in secondary progressive MS trials is undermined by noise in disability measurement. Whereas existing measures can be partially validated in secondary progressive MS, this is not the case in relapsing-remitting MS. Here, examination of widely used definitions of treatment failure demonstrated that disability progression was no more likely than similarly defined improvement. Existing definitions of disease progression in short-term intervention trials in relapsing-remitting patients reflect random variation, measurement error, and remitting relapses. CONCLUSION: Clinical surrogates of unremitting disability used in trials of relapsing-remitting multiple sclerosis cannot be validated. Trials have been too short or degrees of disability change too small to measure the key outcomes. These analyses highlight the difficulty in determining effectiveness of therapy in chronic diseases.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Rating neurologic impairment in multiple sclerosis: An expanded disability status scale (EDSS)
Kurtzke, J. F. (1983) · Neurology · doi:10.1212/wnl.33.11.1444 · Cited by 15,011
Cited by
The Natural History of Adult Crohn's Disease in Population-Based Cohorts
Peyrin-Biroulet, L., Loftus, E. V., Colombel, J.-F., & Sandborn, W. J. (2010) · American Journal of Gastroenterology · doi:10.1038/ajg.2009.579 · Cited by 1,047
Kappos, L., Bar-Or, A., Cree, B. A. C., Fox, R. J., Giovannoni, G., Gold, R., Vermersch, P., Arnold, D. L., Arnould, S., Scherz, T., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(18)30475-6 · Cited by 942
Meyer-Moock, S., Feng, Y.-S., Maeurer, M., Dippel, F.-W., & Kohlmann, T. (2014) · BMC Neurology · doi:10.1186/1471-2377-14-58 · Cited by 639
Impact of Walking Impairment in Multiple Sclerosis: Perspectives of Patients and Care Partners
LaRocca, N. G. (2011) · The Patient: Patient-Centered Outcomes Research · doi:10.2165/11591150-000000000-00000 · Cited by 507
Mitochondrial changes within axons in multiple sclerosis
Mahad, D. J., Ziabreva, I., Campbell, G., Lax, N., White, K., Hanson, P. S., Lassmann, H., & Turnbull, D. M. (2009) · Brain · doi:10.1093/brain/awp046 · Cited by 454
Metadata
- Authors
- Ebers, G. C., Heigenhauser, L., Daumer, M., Lederer, C., & Noseworthy, J. H.
- Venue
- Neurology
- Published
- 2008-08-26
- Volume
- 71
- Issue
- 9
- Pages
- 624-631
- ISSN
- 0028-3878 (ISSN-L)
- 1526-632X
- OpenAlex
- W2035282943
- Cited by
- 180
- References
- 1
- FWCI
- 13.27
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Disability as an outcome in MS clinical trials. https://app.cochat.ai/papers/10.1212/01.wnl.0000313034.46883.16
- The paper
- Ebers, G. C., Heigenhauser, L., Daumer, M., Lederer, C., & Noseworthy, J. H. (2008). Disability as an outcome in MS clinical trials. Neurology. https://doi.org/10.1212/01.wnl.0000313034.46883.16
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.